Ofatumumab Shows Limited Activity in Previously Untreated Follicular Lymphoma

In this study, single-agent ofatumumab did not show superiority to rituximab or obinutuzumab, raising the question of whether ofatumumab should have a role in the treatment of follicular lymphoma.

Source: CancerNetwork - February 20, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news